| 1 | Stromal Tumor-Infiltrating Lymphocytes in Hormone Receptor–Positive/HER2 Negative Metastatic Breast Cancer | 4.8 | 2 | Citations (PDF) |
| 2 | Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial | 4.9 | 1 | Citations (PDF) |
| 3 | Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial | 4.9 | 6 | Citations (PDF) |
| 4 | Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study | 4.7 | 1 | Citations (PDF) |
| 5 | Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy | 2.8 | 9 | Citations (PDF) |
| 6 | Reporting on invasive lobular breast cancer in clinical trials: a systematic review | 6.4 | 21 | Citations (PDF) |
| 7 | Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases | 2.6 | 3 | Citations (PDF) |
| 8 | Research autopsy programmes in oncology: shared experience from 14 centres across the world | 4.9 | 14 | Citations (PDF) |
| 9 | Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium | 4.8 | 27 | Citations (PDF) |
| 10 | Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program | 6.4 | 16 | Citations (PDF) |
| 11 | Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review | 4.7 | 9 | Citations (PDF) |
| 12 | International survey on invasive lobular breast cancer identifies priority research questions | 6.4 | 8 | Citations (PDF) |
| 13 | Dissecting the immune infiltrate of primary luminal B‐like breast carcinomas in relation to age | 4.9 | 2 | Citations (PDF) |
| 14 | A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling | 22.5 | 140 | Citations (PDF) |
| 15 | Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer | 4.9 | 58 | Citations (PDF) |
| 16 | Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer | 4.9 | 10 | Citations (PDF) |
| 17 | Obesity-associated changes in molecular biology of primary breast cancer | 13.7 | 55 | Citations (PDF) |
| 18 | MAGI1 Prevents Senescence and Promotes the DNA Damage Response in ER+ Breast Cancer | 4.6 | 2 | Citations (PDF) |
| 19 | Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors | 3.8 | 0 | Citations (PDF) |
| 20 | Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer | 3.8 | 3 | Citations (PDF) |
| 21 | Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type | 4.9 | 6 | Citations (PDF) |
| 22 | Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases | 6.4 | 8 | Citations (PDF) |
| 23 | Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma | 3.3 | 47 | Citations (PDF) |
| 24 | Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial | 2.3 | 9 | Citations (PDF) |
| 25 | Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer | 6.5 | 28 | Citations (PDF) |
| 26 | Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer | 6.4 | 14 | Citations (PDF) |
| 27 | Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer | 9.9 | 132 | Citations (PDF) |
| 28 | Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights | 5.5 | 89 | Citations (PDF) |
| 29 | ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast | 2.3 | 21 | Citations (PDF) |
| 30 | Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer | 4.8 | 42 | Citations (PDF) |
| 31 | The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer | 6.4 | 6 | Citations (PDF) |
| 32 | Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast | 13.7 | 125 | Citations (PDF) |
| 33 | Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer | 4.6 | 47 | Citations (PDF) |
| 34 | Does Physical Activity Have an Impact on Recurrence Dynamics in Early Breast Cancer Patients? | 2.5 | 11 | Citations (PDF) |
| 35 | Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ | 6.4 | 24 | Citations (PDF) |
| 36 | A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer | 33.0 | 737 | Citations (PDF) |
| 37 | The genomic landscape of carcinomas with mucinous differentiation | 3.4 | 18 | Citations (PDF) |
| 38 | Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors | 22.5 | 74 | Citations (PDF) |
| 39 | Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer | 6.4 | 3 | Citations (PDF) |
| 40 | Is cancer biology different in older patients? | 10.3 | 145 | Citations (PDF) |
| 41 | Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy | 4.6 | 47 | Citations (PDF) |
| 42 | Heterogeneity of Circulating Tumor Cell–Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response | 3.8 | 12 | Citations (PDF) |
| 43 | Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer | 2.3 | 6 | Citations (PDF) |
| 44 | Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach | 4.6 | 186 | Citations (PDF) |
| 45 | Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome | 9.7 | 38 | Citations (PDF) |
| 46 | Digital analysis of distant and cancer-associated mammary adipocytes | 2.3 | 12 | Citations (PDF) |
| 47 | Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer | 6.8 | 35 | Citations (PDF) |
| 48 | Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes | 2.3 | 16 | Citations (PDF) |
| 49 | 67P Digital analysis of distant and cancer-associated adipocytes in breast cancer | 9.9 | 0 | Citations (PDF) |
| 50 | Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer | 2.3 | 14 | Citations (PDF) |
| 51 | MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer | 3.8 | 22 | Citations (PDF) |
| 52 | Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients | 6.4 | 29 | Citations (PDF) |
| 53 | Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy | 4.6 | 80 | Citations (PDF) |
| 54 | The circular RNome of primary breast cancer | 4.6 | 101 | Citations (PDF) |
| 55 | Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer | 11.6 | 4 | Citations (PDF) |
| 56 | A key genomic subtype associated with lymphovascular invasion in invasive breast cancer | 5.5 | 35 | Citations (PDF) |
| 57 | Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy | 2.3 | 28 | Citations (PDF) |
| 58 | Tumor dormancy at bedside: A late awakening | 2.3 | 10 | Citations (PDF) |
| 59 | Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer | 4.6 | 50 | Citations (PDF) |
| 60 | ESR1 mutations in metastatic lobular breast cancer patients | 6.4 | 34 | Citations (PDF) |
| 61 | Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer | 4.7 | 31 | Citations (PDF) |
| 62 | Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer | 4.7 | 38 | Citations (PDF) |
| 63 | Immune Infiltration in Invasive Lobular Breast Cancer | 4.6 | 111 | Citations (PDF) |
| 64 | A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer | 9.9 | 58 | Citations (PDF) |
| 65 | Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations | 6.4 | 30 | Citations (PDF) |
| 66 | Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer | 6.5 | 121 | Citations (PDF) |
| 67 | Transcriptomic and genomic features of invasive lobular breast cancer | 13.7 | 44 | Citations (PDF) |
| 68 | Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations | 13.7 | 166 | Citations (PDF) |
| 69 | Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer | 4.8 | 116 | Citations (PDF) |
| 70 | Recurrence dynamics of breast cancer according to baseline body mass index | 4.9 | 41 | Citations (PDF) |
| 71 | Genomic Evolution of Breast Cancer Metastasis and Relapse | 33.0 | 651 | Citations (PDF) |
| 72 | The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group | 6.4 | 12 | Citations (PDF) |
| 73 | DNA methylation–based immune response signature improves patient diagnosis in multiple cancers | 10.6 | 149 | Citations (PDF) |
| 74 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences | 37.9 | 2,144 | Citations (PDF) |
| 75 | Loss of
ARID1A
Activates
ANXA1
, which Serves as a Predictive Biomarker for Trastuzumab Resistance | 6.8 | 57 | Citations (PDF) |
| 76 | Epstein–Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation | 9.7 | 78 | Citations (PDF) |
| 77 | Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration | 13.7 | 127 | Citations (PDF) |
| 78 | The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence | 14.3 | 24 | Citations (PDF) |
| 79 | Catalog of genetic progression of human cancers: breast cancer | 6.9 | 19 | Citations (PDF) |
| 80 | Characterization of human breast cancer tissues by infrared imaging | 3.1 | 81 | Citations (PDF) |
| 81 | Uncovering the genomic heterogeneity of multifocal breast cancer | 4.9 | 79 | Citations (PDF) |
| 82 | Evolving paradigms in multifocal breast cancer | 13.7 | 40 | Citations (PDF) |
| 83 | Subclonal diversification of primary breast cancer revealed by multiregion sequencing | 33.0 | 807 | Citations (PDF) |
| 84 | Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells | 4.6 | 99 | Citations (PDF) |
| 85 | Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer | 7.1 | 52 | Citations (PDF) |
| 86 | Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome | 6.3 | 216 | Citations (PDF) |
| 87 | The Technologically Integrated Oncosimulator: Combining Multiscale Cancer Modeling With Information Technology in the In Silico Oncology Context | 5.4 | 35 | Citations (PDF) |
| 88 | Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology | 3.3 | 56 | Citations (PDF) |
| 89 | Impact of tumor sequencing on the use of anticancer drugs | 2.1 | 21 | Citations (PDF) |
| 90 | Informed Consent, Biobank Research, and Locality | 1.0 | 13 | Citations (PDF) |
| 91 | TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers | 4.1 | 64 | Citations (PDF) |
| 92 | Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment | 3.1 | 65 | Citations (PDF) |
| 93 | Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes | 36.3 | 422 | Citations (PDF) |
| 94 | Biology of breast cancer during pregnancy using genomic profiling | 3.5 | 67 | Citations (PDF) |
| 95 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | 9.9 | 1,152 | Citations (PDF) |
| 96 | Signatures of mutational processes in human cancer | 37.9 | 9,399 | Citations (PDF) |
| 97 | Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients | 2.1 | 6 | Citations (PDF) |
| 98 | Change in the microenvironment of breast cancer studied by FTIR imaging | 3.1 | 92 | Citations (PDF) |
| 99 | Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding | 3.1 | 46 | Citations (PDF) |
| 100 | Genomic grade adds prognostic value in invasive lobular carcinoma | 9.9 | 68 | Citations (PDF) |
| 101 | TOP2A Protein by Quantitative Immunofluorescence As a Predictor of Response to Epirubicin in the Neoadjuvant Treatment of Breast Cancer | 2.3 | 11 | Citations (PDF) |
| 102 | Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis | 2.3 | 28 | Citations (PDF) |
| 103 | CD4+ follicular helper T cell infiltration predicts breast cancer survival | 10.6 | 1,012 | Citations (PDF) |
| 104 | Next-generation sequencing in breast cancer | 2.1 | 92 | Citations (PDF) |
| 105 | A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes | 4.6 | 298 | Citations (PDF) |
| 106 | Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment | 6.8 | 52 | Citations (PDF) |
| 107 | Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays? | 5.0 | 11 | Citations (PDF) |
| 108 | 9O_PR Gene Modules and Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. A Pooled Analysis | 9.9 | 4 | Citations (PDF) |
| 109 | The landscape of cancer genes and mutational processes in breast cancer | 37.9 | 1,649 | Citations (PDF) |
| 110 | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data | 27.4 | 181 | Citations (PDF) |
| 111 | Multiple-input multiple-output causal strategies for gene selection | 3.0 | 4 | Citations (PDF) |
| 112 | Gene Profiling Assay and Application: The Predictive Role in Primary Therapy | 1.7 | 11 | Citations (PDF) |
| 113 | Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response | 3.0 | 4 | Citations (PDF) |
| 114 | DNA methylation profiling reveals a predominant immune component in breast cancers | 7.1 | 234 | Citations (PDF) |
| 115 | International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010) | 1.7 | 65 | Citations (PDF) |
| 116 | Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions | 6.5 | 36 | Citations (PDF) |
| 117 | Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer | 2.3 | 216 | Citations (PDF) |
| 118 | Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients | 2.1 | 58 | Citations (PDF) |
| 119 | Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer | 0.8 | 0 | Citations (PDF) |
| 120 | An advanced discrete state–discrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study | 1.6 | 44 | Citations (PDF) |
| 121 | Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer | 33.0 | 338 | Citations (PDF) |
| 122 | Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials | 27.4 | 129 | Citations (PDF) |
| 123 | Doubling back on centromere 17 in early breast cancer | 27.4 | 0 | Citations (PDF) |
| 124 | A fuzzy gene expression-based computational approach improves breast cancer prognostication | 8.1 | 51 | Citations (PDF) |
| 125 | Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers | 3.4 | 51 | Citations (PDF) |
| 126 | ‘In Silico’ Oncology for Clinical Decision Making in the Context of Nephroblastoma | 0.2 | 20 | Citations (PDF) |
| 127 | Post-genomic clinical trials - the perspective of ACGT | 0.9 | 1 | Citations (PDF) |
| 128 | Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH | 1.4 | 39 | Citations (PDF) |
| 129 | Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues | 3.3 | 80 | Citations (PDF) |
| 130 | The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial | 1.7 | 73 | Citations (PDF) |
| 131 | A significant proportion of elderly patients develop hormone-dependant “luminal-B” tumours associated with aggressive characteristics | 5.0 | 53 | Citations (PDF) |
| 132 | A Semantic Grid Infrastructure Enabling Integrated Access and Analysis of Multilevel Biomedical Data in Support of Postgenomic Clinical Trials on Cancer | 2.1 | 33 | Citations (PDF) |
| 133 | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen | 3.3 | 318 | Citations (PDF) |
| 134 | Comparison of prognostic gene expression signatures for breast cancer | 3.3 | 128 | Citations (PDF) |
| 135 | Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures | 4.7 | 793 | Citations (PDF) |
| 136 | Gene expression predictors in breast cancer: Current status, limitations and perspectives | 4.9 | 54 | Citations (PDF) |
| 137 | A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? | 4.7 | 212 | Citations (PDF) |
| 138 | p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial | 9.9 | 50 | Citations (PDF) |
| 139 | Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade | 16.9 | 736 | Citations (PDF) |
| 140 | In Reply | 16.9 | 0 | Citations (PDF) |
| 141 | When should I start using a new biomarker: Focus on expression arrays? | 0.5 | 2 | Citations (PDF) |
| 142 | Predicting risk of breast cancer recurrence using gene-expression profiling | 1.5 | 12 | Citations (PDF) |
| 143 | Estrogens decrease γ-ray–induced senescence and maintain cell cycle progression in breast cancer cells independently of p53 | 1.5 | 20 | Citations (PDF) |
| 144 | Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis | 4.6 | 1,917 | Citations (PDF) |
| 145 | Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients | 4.3 | 40 | Citations (PDF) |
| 146 | Gene expression profiling in breast cancer | 9.9 | 32 | Citations (PDF) |
| 147 | Post-genomic clinical trials: the perspective of ACGT | 0.9 | 4 | Citations (PDF) |
| 148 | Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State | 3.8 | 2 | Citations (PDF) |
| 149 | ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer | 13.7 | 3 | Citations (PDF) |
| 150 | Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue | 13.7 | 0 | Citations (PDF) |
